Autopsy report · NCT02110784

Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria

“Low recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 10 months before it stopped.
• 27 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Alfasigma S.p.A.

Sponsor type

Industry

Conditions

Malaria, Vivax

Interventions

Eurartesim tablets

Participants

27

Sites

13

Countries

France, Germany, Israel, Italy, Netherlands, Spain, Switzerland

Trials that died the same way

• Impact of Methadone on Prolonged Mechanical Ventilation in Patients on Continuous Treatment With Opioids
  “very low recruitment” (95% match in meaning)
• Study of Psychomotor Development and Attachment in Children Aged 6 to 30 Months With Oral Disorder
  “Recruitment too low” (92% match in meaning)
• Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
  “Poor recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.